# BPC-157: Research Overview > BPC-157: Research Overview — Formula1 Peptides — A cited research summary of BPC-157, the gastric pentadecapeptide studied for angiogenesis-driven tissue repair. Mechanism, human pilot data, safety cautions, and WADA/FDA status — no dosing advice. **01 / RECOVERY & TISSUE REPAIR** A stable gastric-derived pentadecapeptide studied in animal models for angiogenesis and cytoprotection, with one small human safety pilot to date. ## The short version BPC-157 is a synthetic, 15-amino-acid peptide based on a fragment of a protein naturally found in human gastric juice. In *animal* studies it is described as **cytoprotective** — protecting and helping repair tissue — with the most consistent mechanism being new blood-vessel growth (angiogenesis) around injured tissue [4]. Most of what is known comes from rodent research; as of a 2025 review, only three small human pilot studies exist, and no large controlled human trial has been run [2]. It is not an approved medicine anywhere, it is sold strictly for laboratory research use, and it is banned in competitive sport by the World Anti-Doping Agency. Nothing on this page recommends using it or names a dose to take — doses mentioned below are exactly what a cited study used in animals or in the tiny human pilot, never a suggestion. ## What it is BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a partial sequence of a human gastric-juice protein. Its molecular formula is C62H98N16O22. It circulates in the research literature under several names, including Pentadecapeptide BPC 157, PL 14736, and PLD-116, and is classified as an unapproved, investigational research chemical rather than a drug. ## How it works The best-characterized mechanism is up-regulation and internalization of the VEGFR2 receptor, with downstream VEGFR2-Akt-eNOS (nitric oxide) signaling — a pathway that drives new blood-vessel formation and was shown to increase vessel density and speed blood-flow recovery in ischemic muscle in animal and cell models [4]. Additional reported routes in the corpus include FAK-paxillin signaling associated with cell migration, sensitization of the growth-hormone receptor in tendon fibroblasts, and effects on the nitric-oxide system and several neurotransmitter pathways. The foundational cytoprotection work — reduced gastric ulcer size and faster ulcer healing in rats, with intramuscular delivery outperforming intragastric delivery — dates back to 2004 and remains one of the most cited studies in the field [5]. ## What the research shows *Human safety pilot.* A first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults (a 58-year-old man and a 68-year-old woman); it was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [1]. This is a two-person safety observation, not an efficacy trial, and the study's own authors frame it that way. *State of the human evidence.* A 2025 narrative review concludes that, despite broad preclinical support, human data remain extremely limited — "only three pilot studies have examined BPC-157 in humans" — that rigorous, large-scale trials are lacking, and that BPC-157 should be treated as investigational given the regulatory controversy and unregulated availability [2]. *Pharmacokinetics.* The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (roughly 14–19% in rats, 45–51% in dogs), and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism, with excretion via urine and bile [3]. *Angiogenesis mechanism.* Across chick chorioallantoic-membrane assays, a rat hindlimb-ischemia model, and human vascular endothelial cells, BPC-157 up-regulated VEGFR2 expression and promoted its internalization, activating the VEGFR2-Akt-eNOS pathway; blocking endocytosis blocked the effect, and treated animals showed increased vessel density and faster blood-flow recovery [4]. *Foundational ulcer study.* In Wistar rats, BPC-157 reduced gastric-ulcer area and accelerated healing, with an ulcer-formation-inhibition ratio of roughly 45.7–65.6% at the higher doses tested, and accelerated rebuilding of the glandular epithelium and granulation tissue [5]. ## Reported effects, cautions & safety The following community-reported effects are anecdotal, not clinical evidence. They come from peptide-user forums, wellness-clinic write-ups, and narrative-review summaries of online reports — never from a controlled human trial — and no dose appears in any of it. *Reported benefits (anecdotal):* the most frequent reason people in research-use communities describe trying BPC-157 is faster-feeling recovery from tendon, ligament and joint injuries — tennis elbow, rotator-cuff strain, old sprains — often within the first one to three weeks. Others describe less joint stiffness and easier movement, improved gut symptoms (plausible given its gastric-tissue origin), a general sense of reduced inflammation, faster skin and wound healing, and occasionally better sleep or mood. All of it is self-reported and has not been measured in a controlled human study. *Reported adverse effects (anecdotal):* the most common complaint is a brief, minor injection-site reaction — stinging, redness, or a small bump that typically fades within a day. Less commonly reported: mild nausea or stomach upset (more often with oral products), first-week fatigue, headache, brief dizziness after injecting, transient flushing or warmth, and — rarely — heart palpitations, which commentators treat as a reason to stop and seek medical evaluation. *Cited cautions:* the human evidence base is extremely thin, resting almost entirely on rodent studies plus a handful of small, uncontrolled human pilots, and a large share of the foundational literature comes from one research group, limiting independent replication [2]. BPC-157 is not an approved drug and unregulated products are not verified for identity or purity [2]. Its strong pro-angiogenic activity raises a theoretical, mechanism-based concern in active or suspected cancer, since tumors also depend on new blood-vessel growth [4]. It is prohibited at all times in competitive sport under WADA's non-approved-substances category, and it has not been studied for safety in pregnancy, breastfeeding, or children. ## Where it fits in recovery & tissue-repair research Within the high-performance-repair frame this site uses, BPC-157's angiogenesis mechanism [4] is what makes it relevant to return-to-play questions: new blood-vessel supply is a prerequisite for tissue to remodel under renewed load. It is the more gut-adjacent of the three compounds on this desk — its origin and much of its foundational data come from gastric-tissue research [5] — while [TB-500](/tb-500) leans more toward cell-migration and structural remodeling, and [KLOW](/klow) folds both of them into a broader, untested combination. See the [comparison page](/compare) for the full side-by-side. --- Formula1 Peptides is an independent tissue-repair literature review, not a clinic, not a formulator, and not a substitute for reading the cited studies yourself.